[go: up one dir, main page]

BRPI0417072B8 - "use of an interleukin-6(il-6) antagonist". - Google Patents

"use of an interleukin-6(il-6) antagonist".

Info

Publication number
BRPI0417072B8
BRPI0417072B8 BRPI0417072A BRPI0417072A BRPI0417072B8 BR PI0417072 B8 BRPI0417072 B8 BR PI0417072B8 BR PI0417072 A BRPI0417072 A BR PI0417072A BR PI0417072 A BRPI0417072 A BR PI0417072A BR PI0417072 B8 BRPI0417072 B8 BR PI0417072B8
Authority
BR
Brazil
Prior art keywords
interleukin
antagonist
vasculitis
agent
preventive
Prior art date
Application number
BRPI0417072A
Other languages
Portuguese (pt)
Inventor
Nakahara Hideko
Nishimoto Norihiro
Kishimoto Tadamitsu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34708761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0417072(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0417072A publication Critical patent/BRPI0417072A/en
Publication of BRPI0417072B1 publication Critical patent/BRPI0417072B1/en
Publication of BRPI0417072B8 publication Critical patent/BRPI0417072B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"agente preventivo para a vasculite". para fornecer um agente preventivo e/ou terapêutico para a vasculite tal como poliarterite nodosa, a sindrome de aortite e uma vasculite que é associada com anormalidades imunológicas, dito agente compreendendo um antagonistas da interleucina-6 (il-6) como um ingrediente ativo."preventive agent for vasculitis". to provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, aortitis syndrome and a vasculitis that is associated with immunological abnormalities, said agent comprising an interleukin-6 (il-6) antagonist as an active ingredient.

BRPI0417072A 2003-12-19 2004-12-17 "use of an interleukin-6(il-6) antagonist". BRPI0417072B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003423517 2003-12-19
JP2003-423517 2003-12-19
PCT/JP2004/019463 WO2005061000A1 (en) 2003-12-19 2004-12-17 Remedy for angitis

Publications (3)

Publication Number Publication Date
BRPI0417072A BRPI0417072A (en) 2007-03-13
BRPI0417072B1 BRPI0417072B1 (en) 2017-10-24
BRPI0417072B8 true BRPI0417072B8 (en) 2021-05-25

Family

ID=34708761

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417072A BRPI0417072B8 (en) 2003-12-19 2004-12-17 "use of an interleukin-6(il-6) antagonist".

Country Status (21)

Country Link
US (1) US20140079695A1 (en)
EP (1) EP1707215B1 (en)
JP (1) JP4785534B2 (en)
KR (1) KR101218532B1 (en)
CN (1) CN1893979B (en)
AR (1) AR048210A1 (en)
AT (1) ATE549034T1 (en)
AU (1) AU2004305379B2 (en)
BR (1) BRPI0417072B8 (en)
CA (1) CA2549467C (en)
CO (1) CO5700792A2 (en)
DK (1) DK1707215T3 (en)
ES (1) ES2382809T3 (en)
IL (1) IL176122A (en)
MY (1) MY142986A (en)
NO (1) NO20062718L (en)
NZ (1) NZ547645A (en)
RU (1) RU2379054C2 (en)
TW (1) TWI351967B (en)
WO (1) WO2005061000A1 (en)
ZA (1) ZA200604655B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ES2592271T3 (en) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Polypeptide production methods by regulating the association of polypeptides
BRPI0617378B8 (en) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd USE OF AN IL-6 INHIBITOR TO PRODUCE A PHARMACEUTICAL COMPOSITION TO SUPPRESS DAMAGE TO AN ISLE TRANSPLANTATION AFTER ISLE TRANSPLANTATION; AND IMPROVE THE FEASIBILITY OF AN ISLAND IN AN ISLAND TRANSPLANTATION
US8945558B2 (en) * 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
CN104189907A (en) 2006-01-27 2014-12-10 学校法人庆应义塾 Remedy for disease associated with choroidal angiogenesis
WO2007114325A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5754875B2 (en) 2006-04-07 2015-07-29 国立大学法人大阪大学 Muscle regeneration promoter
JP2010095445A (en) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient
CA2675625C (en) 2007-01-23 2016-09-13 Shinshu University Chronic rejection inhibitor
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
CA2700394C (en) 2007-09-26 2017-10-24 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2834741T3 (en) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anti-NR10 antibody and its use
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
JP4954326B2 (en) 2008-04-11 2012-06-13 中外製薬株式会社 Antigen-binding molecules that repeatedly bind to multiple molecules of antigen
TW201503898A (en) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd Neuroinvasion inhibitor
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
JP5787446B2 (en) 2009-03-19 2015-09-30 中外製薬株式会社 Antibody constant region variants
JP5669732B2 (en) 2009-05-15 2015-02-12 中外製薬株式会社 Anti-AXL antibody
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CA2773522C (en) 2009-10-26 2023-04-18 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
HUE060454T2 (en) 2010-05-28 2023-03-28 Chugai Pharmaceutical Co Ltd Antitumor t cell response enhancer
US8580264B2 (en) 2010-11-08 2013-11-12 Genentech, Inc. Subcutaneously administered anti-IL-6 receptor antibody
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
WO2014200018A1 (en) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
WO2015000865A1 (en) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
SG11201705093UA (en) 2015-02-27 2017-07-28 Chugai Pharmaceutical Co Ltd Composition for treating il-6-related diseases
WO2016159213A1 (en) 2015-04-01 2016-10-06 中外製薬株式会社 Method for producing polypeptide hetero-oligomer
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
CN108368166B (en) 2015-12-28 2023-03-28 中外制药株式会社 Method for improving purification efficiency of polypeptide containing FC region
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
CA3075561A1 (en) 2017-09-13 2019-03-21 Jiangsu Hengrui Medicine Co., Ltd. Il-6r antibody and antigen binding fragment thereof and medical use
WO2019078344A1 (en) 2017-10-20 2019-04-25 学校法人兵庫医科大学 Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CN116327926A (en) 2018-03-15 2023-06-27 中外制药株式会社 Anti-dengue virus antibodies with cross-reactivity to Zika virus and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
KR100249937B1 (en) 1991-04-25 2000-04-01 나가야마 오사무 Reconstituted Human Antibody Against Human Interleukin-6 Receptor
FR2694767B1 (en) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anti-IL6R monoclonal antibodies, and their applications.
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (en) 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
IT1274350B (en) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio INTERLEUCHINA-6 (IL-6) ANTAGONISTS, WHICH CONSIST OF SOLUBLE FORMS OF THE ALFA RECEPTOR OF IL-6, CHANGED IN THE INTERFACE THAT LINKS TO GP 130
IT1274782B (en) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130
JPH08311098A (en) * 1995-05-22 1996-11-26 Daicel Chem Ind Ltd New peptides and interleukin 6 antagonistic agent containing the peptide
AU736282B2 (en) * 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
DE19923961A1 (en) * 1999-05-25 2000-11-30 Euro Nippon Kayaku Gmbh Use of 15-deoxyspergualin for the treatment of hyper-reactive inflammatory and autoimmune diseases
JP2003026699A (en) * 2001-07-13 2003-01-29 Inter Cyto Nano Science Co Ltd Il-6 signal transmission-antagonizing peptide
WO2004039826A1 (en) * 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
FR2833011B1 (en) * 2001-12-04 2004-10-29 Univ Claude Bernard Lyon NOVEL PROTEIN WITH IL-6 INHIBITING ACTIVITY
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases

Also Published As

Publication number Publication date
CA2549467A1 (en) 2005-07-07
ZA200604655B (en) 2007-11-28
TWI351967B (en) 2011-11-11
EP1707215A1 (en) 2006-10-04
NO20062718L (en) 2006-09-18
TW200524630A (en) 2005-08-01
IL176122A0 (en) 2006-10-05
AU2004305379B2 (en) 2011-04-07
BRPI0417072A (en) 2007-03-13
EP1707215B1 (en) 2012-03-14
DK1707215T3 (en) 2012-04-16
HK1095751A1 (en) 2007-05-18
NZ547645A (en) 2009-05-31
CO5700792A2 (en) 2006-11-30
CN1893979B (en) 2011-06-08
CA2549467C (en) 2012-12-11
RU2006126092A (en) 2008-01-27
EP1707215A4 (en) 2009-07-15
CN1893979A (en) 2007-01-10
BRPI0417072B1 (en) 2017-10-24
ATE549034T1 (en) 2012-03-15
IL176122A (en) 2011-07-31
JP4785534B2 (en) 2011-10-05
US20140079695A1 (en) 2014-03-20
AU2004305379A1 (en) 2005-07-07
MY142986A (en) 2011-02-14
KR101218532B1 (en) 2013-01-03
JPWO2005061000A1 (en) 2007-07-12
ES2382809T3 (en) 2012-06-13
WO2005061000A1 (en) 2005-07-07
RU2379054C2 (en) 2010-01-20
AR048210A1 (en) 2006-04-12
KR20060132616A (en) 2006-12-21

Similar Documents

Publication Publication Date Title
BRPI0417072B8 (en) "use of an interleukin-6(il-6) antagonist".
CL2008002207A1 (en) Pharmaceutical composition comprising immunosuppressants to improve the effect in the use of an antagonist of interleukin-6 (il-6) for the treatment of illnesses related to il-6 (div. Sol. 896-04).
UY27740A1 (en) NEW COMPOUNDS
NO20064365L (en) Therapeutic compound
ES2195785B1 (en) NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
HN2002000275A (en) DERIVATIVES OF 1.8 NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
TR200101859T2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
UY27939A1 (en) COMPOUNDS
CR10838A (en) DERIVATIVES OF 2,3-DIHYDROIMIDAZOL [1,2-C] QUINAZOLINE SUBSTITUTED, USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
BRPI0413563A (en) compounds and compositions as inhibitors of tyrosine kinase receptor activity
BR0313371A (en) Compound, use of a compound and disease treatment method
UY27760A1 (en) NEW DERIVATIVES OF PIRROLIDINIO.
BR0214343A (en) 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1
ES2188651T3 (en) GUANILHYDRAZONES FOR THE TREATMENT OF INFLAMMATORY AFFECTIONS.
ECSP034811A (en) DERETADOS HETEROCICLILOXI-, -TIOXI - Y - AMINOBENZAZOLE SUCH AS LIGANDOS 5-HIDROXITRIPTAMINA-6
RS53428B (en) Compositions and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
ECSP045353A (en) DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND APPLICATION AS MEDICATIONS
ECSP045156A (en) INDOLILALQUILAMINE DERIVATIVES AS LIGANDOS 5-HIDROXITRIPTAMINA-6
PA8575601A1 (en) PROCEDURE FOR PREPARATION, MEDICATIONS THAT INCLUDE THESE COMPOUNDS AND THEIR USE
BR0007864A (en) Compound, and, use of a compound
UY27244A1 (en) USE OF ACID- (4´-TRIFLUORMETHYLPHENYL) - AMIDA (Z) -2- CYANO-3- HYDROXI-BUT-2-ENOIC FOR THE TREATMENT OF MULTIPLE SCLEROSIS
PA8532001A1 (en) USEFUL BIFENYL CARBOXAMIDS AS LIPID REDUCING AGENTS
ES2134801T3 (en) CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE.
BRPI0417161A (en) compounds, pharmaceutical compositions, and use of a compound
PA8586801A1 (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF